Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: Estimates from the Centers for Disease Control WONDER database.

Authors

Chinmay Jani

Chinmay Jani

Department of Medicine, Mount Auburn Hospital, Cambridge, MA

Chinmay Jani , Christian Mouchati , Nour Abdallah , Melissa Mariano , Ruchi Tusharkumar Jani , Justin D Salciccioli , Dominic C Marshall , Harpreet Singh , Joseph Shalhoub , Rana R. McKay

Organizations

Department of Medicine, Mount Auburn Hospital, Cambridge, MA, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, Department of Urology Research, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, Department of Internal Medicine, Mount Auburn Hospital, Cambridge, MA, Smt N.H.L. Municipal Medical College, Gujarat, India, Brigham and Women's Hospital, Boston, MA, University of Oxford, Oxford, United Kingdom, Froedtert and Medical College of Wisconsin, Milwaukee, WI, Imperial College of London & Imperial College Healthcare NHS Trust, London, United Kingdom, University of California San Diego, La Jolla, CA

Research Funding

No funding received

Background: In the United States of America (USA), prostate cancer is the most common cancer in men, and it remained the second leading cause of cancer related mortality. It has a disproportionate burden of disease among minorities. In particular, African American (AA) men have a higher incidence and more aggressive disease course. Our study compares trends in prostate cancer mortality in the United States of America (USA) by race and state from 1999 to 2019. Methods: We used the Center for Disease Control (CDC) WONDER database using ICD-10 code C61 to extract mortality data for malignant prostate cancer. Age standardized death rates (ASDRs) are reported per 100,000 population using the USA standard population. ASDRs were divided into American Indian or Alaskan Native, Asian, Black or African American and, Whites and reported by year for each state. Due to the lack of available data in many states, state-wise analyses were done for white and African American men only. We used Joinpoint regression analysis for trends comparison. Results: Between 1999 and 2019, data was analyzed from 50 states of the USA, of which four started collecting data from 2000, one from 2001, one from 2008, and one from 2009. Three states had data until 2018 only. Data was missing for African American men in 17 states. In 2019, ASDR in African American (13.4/100,000) was significantly higher than Whites (7.3/100,000) (p<0.001). The highest ASDR for African American was observed in Nebraska (33.5/100,000), followed by Wisconsin (17.7/100,000). In contrast, the highest ASDR for whites was observed in Alaska (11/100,000), followed by Utah (10.5/100,000) ASDR decreased by 31.8% in White men at the national level, compared to a decline of 44.6% in African American men. ASDR decreased in all states for both races. For White men, the widest drops were in South Dakota (-45.9%) and Kentucky (-47.0%), and the lowest declines in New Hampshire (-11.5%) and Alaska (-16.0%). For African American men, the largest decreases were in Delaware (-57.8%) and Nevada (-55.3%), and the smallest declines were in Kentucky (-14.9%) and Wisconsin (-20.3%). Conclusions: During the last 20 years, the mortality rate from prostate cancer has consistently dropped in all the states of the USA and for all races. Even though a higher decrease in ASDR was observed in the African American and Asian racial groups, ASDR is still higher in African Americans as compared to Whites.

Prostate cancer age-standardized death rate in the USA. (per 100,000 population).

Race
1999 (95% CI)
2019 (95% CI)
Percentage change
African American
24.2 (23.6-24.9)
13.4 (13.1-13.8)
-44.6
White
10.7 (10.5-10.8)
7.3 (7.2-7.4)
-31.8
American Indian or Alaskan Native
6.3 (4.8-8.1)
5.1 (4.3-5.9)
-19.04
Asian
5.8 (5.1-6.5)
3.2 (3-3.5)
-44.82
Total
11.6 (11.5-11.8)
7.7 (7.6-7.8)
-33.62

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Cancer Disparities

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 30)

DOI

10.1200/JCO.2022.40.6_suppl.030

Abstract #

30

Poster Bd #

B1

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Annual Meeting

Clinician documentation of shared decision making for prostate cancer screening.

First Author: Phuong Nhi Le

First Author: Arya Mariam Roy

First Author: Daniel Sabater Minarim

First Author: Karan Jatwani